CDKN2A and ovarian carcinoma: By utilizing the criterion of a semi-quantitative scale as previously described [14], we found that 36% (64/179) and 17% (30/179) of ovarian carcinomas had negative/down-regulated expression of p16Ink4a and p14ARF, respectively.